Monitoring the therapeutic level of meropenem

Therapeutic drug monitoring of meropenem in patients hospitalized in intensive care units of hamadan hospitals

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20111107008022N16

Enrollment

Registered

2024-10-30

Start date

2024-08-22

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1-Patients hospitalized in special care units 2-Patients with septic shock. Severe sepsis with septic shock

Interventions

Intervention group: patients hospitalized in intensive care units receiving at least three doses of meropenem.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients hospitalized in the ICU recipient of at least three doses of meropenem over 18 years old

Exclusion criteria

Exclusion criteria: ESRD patient CKD patient AKI patient Taking medicines that affect the plasma concentration of meropenem

Design outcomes

Primary

Measure	Time frame
Meropenem blood level. Timepoint: Sampling is taken after the fourth dose and half an hour before the fifth dose (one sample), half an hour before the sixth dose (two doses) and half an hour before the seventh dose (three doses). Method of measurement: HPLC Instrument.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKatayoun Derakhshande

Hamedan University of Medical Sciences

Kderakhshandeh@umsha.ac.ir+98 81 3838 1590

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026